Impact of restricted reimbursement on the use of statins in Finland: A register-based study

Medical Care

Volumn 48, Issue 9, 2010, Pages 761-766

  Martikainen, Jaana E ^a   Saastamoinen, Leena K ^a   Korhonen, Maarit J ^b,c   Enlund, Hannes ^c,d   Helin Salmivaara, Arja ^b,e  

^a SOCIAL INSURANCE INSTITUTION   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

^d KUWAIT UNIVERSITY   (Kuwait)

^e HOSPITAL DISTRICT OF HELSINKI AND UUSIMAA   (Finland)

Author keywords

drug use; policy change; register based study; restricted reimbursement; statins

Indexed keywords

ATORVASTATIN; ROSUVASTATIN; SIMVASTATIN; STATIN;

ADULT; ARTICLE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG COST; DRUG USE; FAMILIAL HYPERLIPEMIA; FEMALE; FINLAND; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; REIMBURSEMENT;

FEMALE; FINLAND; FLUOROBENZENES; HEALTH POLICY; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; PHYSICIAN'S PRACTICE PATTERNS; PYRIMIDINES; PYRROLES; REGISTRIES; REIMBURSEMENT MECHANISMS; SULFONAMIDES;

EID: 77955984577     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/MLR.0b013e3181e41bcb     Document Type: Article

References (20)

1. Ess SM, Schneeweiss S, Szucs TD. European healthcare policies for controlling drug expenditure. Pharmacoeconomics. 2003;21:89-103.
2. Puig-Junoy J, Moreno-Torres I. Impact of pharmaceutical prior authorisation policies: A systematic review of the literature. Pharmacoeconomics. 2007;25:637-648.
3. Schneeweiss S. Reference drug programs: Effectiveness and policy implications. Health Policy. 2007;81:17-28.
4. Vogler S, Habl C, Leopold C, et al. PPRI Report, 2008. Available at: http://ppri.oebig.at/Downloads/Publications/PPRI-Report-final.pdf. Accessed January 21, 2010.
5. Fink KS, Byrns PJ. Changing prescribing patterns and increasing prescription expenditures in Medicaid. Ann Fam Med. 2004;2:488-493.
6. Banthin JS, Miller GE. Trends in prescription drug expenditure by Medicaid enrollees. Med Care. 2006;44(suppl 5):I27-I35.
7. Walley T, Folino-Gallo P, Stephens P, et al. Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997-2003. Br J Clin Pharmacol. 2005;60:543-551.
8. Ruokoniemi P, Helin-Salmivaara A, Klaukka T, et al. Shift of statin use towards the elderly in 1995-2005: A nation-wide register study in Finland. Br J Clin Pharmacol. 2008;66:405-410.
9. Kalo Z, Muszbek N, Bodrogi J, et al. Does therapeutic reference pricing always result in cost-containment? The Hungarian evidence. Health Policy. 2007;80:402-412.
10. Stargardt T. The impact of reference pricing on switching behaviour and healthcare utilisation: The case of statins in Germany. Eur J Health Econ. 2010;11:267-277.
11. Tandvårds-och lakemedelsformånsverket, Unnecessarily expensive lipid medicines lose reimbursement today, 2009, Available at: http://www.tlv.se/in-english/news/unnecessarily-expensive-lipid-medicines-lose- reimbursement-today/Accessed January 21, 2010
12. Sakshaug S, Furu K, Karlstad O, et al. Switching statins in Norway after new reimbursement policy\a nationwide prescription study. Br J Clin Pharmacol. 2007;64:476-481.
13. Festoy H, Sveen K, Yu LM, et al. Pharma Profile. Norway: Pharmaceutical Pricing and Reimbursement Information (PPRI); 2008. Available at: http://ppri.oebig.at/Downloads/Results/Norway-PPRI-2008.pdf. Accessed January 21, 2010.
14. Godman B, Bucsics A, Burkhardt T, et al. Insight into recent reforms and initiatives in Austria: Implications for key stakeholders. Expert Rev Pharmacoecon Outcomes Res. 2008;8:357-371.
15. Wettermark B, Godman B, Andersson K, et al. Recent national and regional drug reforms in Sweden: Implications for pharmaceutical companies in Europe. Pharmacoeconomics. 2008;26:537-550.
16. Danish Medicines Agency. Prescription-only medicinal products eligible for conditional reimbursement, 2009. Available at: http://www. dkma.dk/1024/visUKLSArtikel.asp?artikelID=9220. Accessed January 21, 2010.
17. National Agency for Medicines and Social Insurance Institution, Finnish Statistics on Medicines 2002, Helsinki, Finland: National Agency for Medicines and Social Insurance Institution, 2003.
18. WHO Collaborating Centre. ATC/DDD Index 2008. Available at: http://www.whocc.no/atcddd/. Accessed February 24, 2008.
19. Peura S, Rajaniemi S, Kurkijarvi U. Pharma Profile. Finland: Pharmaceutical pricing and reimbursement information (PPRI), 2007. Available at: http://ppri.oebig.at/Downloads/Results/Finland-PPRI-2007.pdf. Accessed January 21, 2010.
20. Devold HM, Molden E, Skurtveit S, et al. Co-medication of statins and CYP3A4 inhibitors before and after introduction of new reimbursement policy. Br J Clin Pharmacol. 2009;67:234-241.